BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 37033931)

  • 1. Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies.
    Senturk ZN; Akdag I; Deniz B; Sayi-Yazgan A
    Front Immunol; 2023; 14():1152551. PubMed ID: 37033931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local and systemic immune profiles of human pancreatic ductal adenocarcinoma revealed by single-cell mass cytometry.
    Brouwer TP; de Vries NL; Abdelaal T; Krog RT; Li Z; Ruano D; Fariña A; Lelieveldt BPF; Morreau H; Bonsing BA; Vahrmeijer AL; Koning F; de Miranda NFCC
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35793870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
    Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
    Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
    Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
    Front Immunol; 2021; 12():643529. PubMed ID: 33679807
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer.
    Stouten I; van Montfoort N; Hawinkels LJAC
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma.
    Graziano V; Dannhorn A; Hulme H; Williamson K; Buckley H; Karim SA; Wilson M; Lee SY; Kaistha BP; Islam S; Thaventhiran JED; Richards FM; Goodwin R; Brais R; Morton JP; Dovedi SJ; Schuller AG; Eyles J; Jodrell DI
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling the impact of sialic acids on the immune landscape and immunotherapy efficacy in pancreatic cancer.
    Boelaars K; Goossens-Kruijssen L; Wang D; de Winde CM; Rodriguez E; Lindijer D; Springer B; van der Haar Àvila I; de Haas A; Wehry L; Boon L; Mebius RE; van Montfoort N; Wuhrer M; den Haan JMM; van Vliet SJ; van Kooyk Y
    J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37940346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
    Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
    Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.
    Joseph AM; Al Aiyan A; Al-Ramadi B; Singh SK; Kishore U
    Front Immunol; 2024; 15():1323198. PubMed ID: 38384463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy.
    Luong T; Golivi Y; Nagaraju GP; El-Rayes BF
    Cytokine Growth Factor Rev; 2022 Dec; 68():107-115. PubMed ID: 36096869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokines chattering in pancreatic ductal adenocarcinoma tumor microenvironment.
    Bhatia R; Bhyravbhatla N; Kisling A; Li X; Batra SK; Kumar S
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):499-510. PubMed ID: 35346801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL-8.
    Chen SJ; Lian GD; Li JJ; Zhang QB; Zeng LJ; Yang KG; Huang CM; Li YQ; Chen YT; Huang KH
    Cancer Med; 2018 Nov; 7(11):5679-5690. PubMed ID: 30311406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the dual role of B cells in solid tumors: implications for head and neck squamous cell carcinoma.
    Bao J; Betzler AC; Hess J; Brunner C
    Front Immunol; 2023; 14():1233085. PubMed ID: 37868967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer.
    Wang R; Hong K; Zhang Q; Cao J; Huang T; Xiao Z; Wang Y; Shuai X
    Acta Biomater; 2023 Oct; 169():451-463. PubMed ID: 37572982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.